META-THRIVE

Abstract:

The main goal of this project is to develop a thymidine phosphorylase (TP) inhibitor as a completely novel oral, intracellular, and targeted therapy for cancer treatment. Beyond basic research, the focus is on advancing its pharmacological and preclinical development, aiming for superior efficacy and a favorable safety profile compared to current therapies.

The project includes several key objectives. First, efforts will focus on optimizing a TP inhibitor with good oral bioavailability through detailed analyses of pharmacokinetic properties and stability. In parallel, the antitumor efficacy of the candidate compound will be validated, both as a standalone treatment and in combination with other therapies, through in vitro and in vivo studies.
Another fundamental aspect of the project will be to better understand how TP inhibition impacts antitumor immune response, which could open the door to new combined therapeutic strategies. Finally, preclinical studies required by regulatory authorities will be conducted to prepare the necessary dossier for authorization to begin human trials.

With these advances, the project aims to position this inhibitor as an innovative oncology therapy, with the potential to significantly improve clinical outcomes and the quality of life of cancer patients.

Leitat’s Role in the Project:

Leitat will act as a beneficiary partner in the META-THRIVE project.